This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Correction

Correction. Reproductive Safety of Second-Generation Antipsychotics: Updated Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics

Adele C. Viguera, MD, MPH; Marlene P. Freeman, MD; Lina Góez-Mogollón, MD, MSc; Alexandra Z. Sosinsky, MS; Sara A. McElheny, BA; Taylor R. Church, BS; Amanda V. Young, BA; Phoebe S. Caplin, BA; David Chitayat, MD; Sonia Hernández-Díaz, MPH, DrPH; and Lee S. Cohen, MD

Published: October 5, 2021

This corrects the article DOI: 10.4088/JCP.20m13745.


In the article “Reproductive Safety of Second-Generation Antipsychotics: Updated Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics” by Adele C. Viguera, MD, MPH, and colleagues, published in the July/August 2021 issue (J Clin Psychiatry 2021;82[4]:20m13745), the fifth psychotropic category listed below “First Trimester Psychotropic Medication Use” in Table 1 has been corrected to “Atypical antidepressants.”

Volume: 82

Quick Links: Bipolar Disorder

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression

Zuranolone was associated with improvements in depressive and anxiety symptoms and was beneficial for insomnia and patient-perceived...

Read More...